Back to Trades
Buy4
Orchestra BioMed Holdings, Inc.
OBIO
Total Value
$1.9M
Net $1.9M bought
Purchases
$1.9M
1 transaction
Company Information
- Company Name
- Orchestra BioMed Holdings, Inc.
- Ticker Symbol
- OBIO
- CIK
- 0001814114
Insider Information
- Role
- Insider
- Location
- NEW YORK, NY
Filing Details
- Filing Date
- Aug 5, 2025
- Transaction Date
- Aug 1, 2025
- Accession Number
- 0000950170-25-102537
- Form Type
- 4
- Net Trading Amount
- $1.9M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Aug 1, 2025 | Common Stock | 700,000 | $2.75 | Purchase | $1.9M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Aug 1, 2025 | Derivative | 1,500,000 | $0.00 | Purchase | $150 |
Footnotes
- (F1)Represents the purchase price for each share of Common Stock purchased by the Reporting Person in the Issuer's registered public offering that closed on August 1, 2025.
- (F2)The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman ("Mr. Edelman") serves as the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of their indirect pecuniary interest therein, and this report shall not be deemed an admission that the Advisor or Mr. Edelman are beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- (F3)The pre-funded warrants are immediately exercisable and will expire on the date they are exercised in full, subject to the Beneficial Ownership Limitation.
- (F4)Represents the purchase price for each pre-funded warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on August 1, 2025.